9 Einträge gefunden

1. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms

   1. Fu, Yuewen
   2. Schroeder, Thomas
   3. Zabelina, Tatiana
   4. Badbaran, Anita
   5. Bacher, Ulrike
   6. Kobbe, Guido
   7. Ayuketang, Francis Ayuk

   2014 - Forschungsinformationssystem des UKE
2. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

   1. Schnittger, Susanne
   2. Bacher, Ulrike
   3. Alpermann, Tamara
   4. Reiter, Andreas
   5. Ulke, Madlen
   6. Dicker, Frank
   7. Eder, Christiane

   2012 - Forschungsinformationssystem des UKE - frei zugänglich
3. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.

   1. Bacher, Ulrike
   2. Weissmann, Sandra
   3. Kohlmann, Alexander
   4. Schindela, Sonja
   5. Alpermann, Tamara
   6. Schnittger, Susanne
   7. Kern, Wolfgang

   2012 - Forschungsinformationssystem des UKE
4. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

   1. Bacher, Ulrike
   2. Schnittger, Susanne
   3. Macijewski, Katja
   4. Grossmann, Vera
   5. Kohlmann, Alexander
   6. Alpermann, Tamara
   7. Kowarsch, Andreas

   2012 - Forschungsinformationssystem des UKE
5. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.

   1. Schnittger, Susanne
   2. Bacher, Ulrike
   3. Eder, Christiane
   4. Dicker, Frank
   5. Alpermann, Tamara
   6. Grossmann, Vera
   7. Kohlmann, Alexander

   2012 - Forschungsinformationssystem des UKE - frei zugänglich
6. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.

   1. Haferlach, Claudia
   2. Bacher, Ulrike
   3. Kohlmann, Alexander
   4. Schindela, Sonja
   5. Alpermann, Tamara
   6. Kern, Wolfgang
   7. Schnittger, Susanne

   2011 - Forschungsinformationssystem des UKE - frei zugänglich
7. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).

   1. Miesner, Miriam
   2. Haferlach, Claudia
   3. Bacher, Ulrike
   4. Weiss, Tamara
   5. Macijewski, Katja
   6. Kohlmann, Alexander
   7. Klein, Hans-Ulrich

   2010 - Forschungsinformationssystem des UKE
8. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.

   1. Bacher, Ulrike
   2. Haferlach, Claudia
   3. Schnittger, Susanne
   4. Kohlmann, Alexander
   5. Kern, Wolfgang
   6. Haferlach, Torsten

   2010 - Forschungsinformationssystem des UKE
9. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

   1. Falini, Brunangelo
   2. Macijewski, Katja
   3. Weiss, Tamara
   4. Bacher, Ulrike
   5. Schnittger, Susanne
   6. Kern, Wolfgang
   7. Kohlmann, Alexander

   2010 - Forschungsinformationssystem des UKE